TerrAscend (TSNDF) Non-Current Assets (2021 - 2026)
TerrAscend (TSNDF) posted quarterly Non-Current Assets of $446.7 million for Q1 2026, down 10.59% year-over-year from $499.5 million in Q1 2025, and little changed quarter-over-quarter from $447.3 million in Q4 2025.
TerrAscend (TSNDF) Non-Current Assets (2021 - 2026) Analysis & Trends
TerrAscend (TSNDF) has reported Non-Current Assets for 6 consecutive years, with $446.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 10.59% year-over-year to $446.7 million; the TTM figure through Mar 2026 stood at $446.7 million (down 10.59% YoY), while the FY2025 annual figure was $447.3 million, up 3.93% from the prior year.
- Non-Current Assets steadied at $446.7 million in Q1 2026 per TSNDF's latest filing, from $447.3 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $871.3 million in Q2 2022 and bottomed at $430.3 million in Q4 2024.
- Historically, Non-Current Assets has averaged $568.8 million across 5 years, with a median of $557.9 million in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Assets surged 41.56% — and 2023, when it plunged 30.79%.
- TerrAscend's Non-Current Assets stood at $579.6 million in 2022, then retreated by 2.75% to $563.6 million in 2023, then fell by 23.65% to $430.3 million in 2024, then advanced by 3.93% to $447.3 million in 2025, then declined by 0.14% to $446.7 million in 2026.
- Business Quant data shows TSNDF's Non-Current Assets at $446.7 million in Q1 2026, $447.3 million in Q4 2025, and $435.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 2.96 Bn |
| 10 | TerrAscend | 182.53 Mn | 140.41 Mn | 36.25 Mn | 440.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 440.24 Mn |
| Mar 31, 2026 | 446.66 Mn |
| Dec 31, 2025 | 447.27 Mn |
| Sep 30, 2025 | 435.90 Mn |
| Jun 30, 2025 | 438.92 Mn |
| Mar 31, 2025 | 499.54 Mn |
| Dec 31, 2024 | 430.34 Mn |
| Sep 30, 2024 | 551.22 Mn |
| Jun 30, 2024 | 555.44 Mn |
| Mar 31, 2024 | 557.88 Mn |
| Dec 31, 2023 | 563.63 Mn |
| Sep 30, 2023 | 627.45 Mn |
| Jun 30, 2023 | 615.12 Mn |
| Mar 31, 2023 | 587.79 Mn |
| Dec 31, 2022 | 579.59 Mn |
| Sep 30, 2022 | 612.09 Mn |
| Jun 30, 2022 | 871.30 Mn |
| Mar 31, 2022 | 849.27 Mn |
| Dec 31, 2021 | 409.45 Mn |